Can you summarize the European Association of Urology (EAU) recommendations for evaluation, management, and follow‑up of lower urinary tract symptoms (LUTS) in women?

EAU Recommendations for LUTS in Women: Evaluation to Management and Follow-up

I must note that the provided evidence primarily addresses urinary tract infections and male LUTS, not the comprehensive evaluation and management of female LUTS as requested. However, I can provide guidance based on the available EAU female LUTS guidelines referenced in the evidence 1, 2.

Initial Evaluation

Begin with a focused history targeting specific symptom patterns: storage symptoms (urgency, frequency, nocturia, incontinence), voiding symptoms (hesitancy, weak stream, straining, incomplete emptying), and post-micturition symptoms (post-void dribbling, sensation of incomplete emptying) 1.

Key Diagnostic Components:

• Symptom questionnaires: Use validated tools to quantify symptom severity and impact on quality of life
• Bladder diary: 3-day voiding diary documenting frequency, volume, urgency episodes, and incontinence events
• Urinalysis: Rule out infection and hematuria
• Post-void residual (PVR) measurement: Essential for detecting incomplete bladder emptying
• Pelvic examination: This is critical and should be performed routinely - assess for pelvic organ prolapse, pelvic floor muscle function, atrophic vaginitis, and anatomical abnormalities 1

Important Caveat:

Recent data shows only 8.7% of male urologists routinely perform pelvic examinations on women with LUTS compared to 85.7% of female urologists 3. This represents a significant gap in standard care that must be addressed - pelvic examination is essential for proper diagnosis and should not be omitted.

Management by Condition

Overactive Bladder (OAB)

First-line therapy consists of behavioral interventions 1:

• Bladder training with scheduled voiding
• Fluid management (not restriction, but optimization)
• Caffeine reduction
• Pelvic floor muscle training

Second-line pharmacotherapy 1:

• Antimuscarinics (anticholinergics)
• β3-adrenergic agonists (mirabegron)

Third-line interventions 1:

• Intradetrusor botulinum toxin injections
• Sacral neuromodulation
• Percutaneous tibial nerve stimulation

Stress Urinary Incontinence (SUI)

Conservative management first 1:

• Supervised pelvic floor muscle training (minimum 3 months)
• Weight loss if BMI >30
• Lifestyle modifications

Surgical intervention when conservative measures fail 1:

• Mid-urethral sling procedures (retropubic or transobturator approach)
• Bulking agents for selected cases
• Colposuspension for specific indications

Mixed Urinary Incontinence (MUI)

Treat the predominant symptom first 1:

• If urgency predominates: follow OAB pathway
• If stress component predominates: follow SUI pathway
• Often requires sequential or combined treatment approaches

Underactive Bladder (UAB)

Management focuses on ensuring complete emptying 2:

• Timed voiding with double voiding technique
• Clean intermittent catheterization if PVR consistently >200-300 mL
• Address underlying causes (medications, neurological screening)
• Avoid surgical intervention unless specific obstruction identified

Bladder Outlet Obstruction (BOO)

Identify and address the specific cause 2:

• Urethral stricture: dilation or urethroplasty
• Pelvic organ prolapse: pessary or surgical repair
• Pelvic floor dysfunction: pelvic floor physical therapy, biofeedback
• Urethral diverticulum: surgical excision

Nocturia

Systematic approach based on etiology 2:

• Treat underlying conditions (sleep apnea, heart failure, diabetes)
• Fluid restriction 2-4 hours before bedtime
• Desmopressin for nocturnal polyuria (check sodium levels)
• Treat concurrent OAB if present

Special Considerations for Postmenopausal Women

Vaginal estrogen therapy has strong evidence for preventing recurrent UTIs and improving urogenital atrophy symptoms 4. Risk factors requiring attention include:

• Atrophic vaginitis
• Pelvic organ prolapse (cystocele)
• Elevated post-void residual volumes
• Urinary incontinence

Follow-up Strategy

Structured reassessment at 4-12 weeks depending on intervention:

• Repeat symptom questionnaires to quantify improvement
• Reassess PVR if initially elevated
• Bladder diary to document objective changes
• Adjust treatment based on response

For conservative management: Continue for minimum 3 months before declaring failure

For pharmacotherapy: Assess efficacy and tolerability at 4-8 weeks, adjust dose or switch agents as needed

For surgical intervention: Follow-up at 6 weeks, 6 months, and annually to monitor for complications and recurrence

Critical Pitfalls to Avoid

• Do not skip pelvic examination - it is essential for proper diagnosis despite being frequently omitted 3
• Do not perform extensive workup (cystoscopy, imaging) in young women without risk factors or red flags 4
• Do not treat empirically without proper assessment - symptom patterns guide specific interventions
• Do not ignore elevated PVR - this requires investigation and management to prevent complications